Celldex Therapeutics, Inc. (CLDX)

$28.71

+0.46

(+1.63%)▲

Live

Performance

  • $27.54
    $28.72
    $28.71
    downward going graph

    4.08%

    Downside

    Day's Volatility :4.09%

    Upside

    0.02%

    downward going graph
  • $22.11
    $53.18
    $28.71
    downward going graph

    22.99%

    Downside

    52 Weeks Volatility :58.42%

    Upside

    46.01%

    downward going graph

Returns

PeriodCelldex Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-22.26%
3.6%
0.0%
6 Months
-27.28%
10.2%
0.0%
1 Year
16.16%
19.6%
0.0%
3 Years
-39.25%
16.8%
-23.0%

Highlights

Market Capitalization
1.9B
Book Value
$12.28
Earnings Per Share (EPS)
-2.75
PEG Ratio
0.0
Wall Street Target Price
67.4
Profit Margin
0.0%
Operating Margin TTM
-1854.16%
Return On Assets TTM
-17.83%
Return On Equity TTM
-27.53%
Revenue TTM
8.3M
Revenue Per Share TTM
0.15
Quarterly Revenue Growth YOY
832.1%
Gross Profit TTM
-79.9M
EBITDA
-160.2M
Diluted Eps TTM
-2.75
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.44
EPS Estimate Next Year
-3.0
EPS Estimate Current Quarter
-0.59
EPS Estimate Next Quarter
-0.61

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Celldex Therapeutics, Inc.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 134.76%

Current $28.71
Target $67.40

Company Financials

FY18Y/Y Change
Revenue
9.5M
↓ 25.15%
Net Income
-151.2M
↑ 62.51%
Net Profit Margin
-1.6K%
↓ 855.01%
FY19Y/Y Change
Revenue
3.6M
↓ 62.54%
Net Income
-50.4M
↓ 66.68%
Net Profit Margin
-1.4K%
↑ 175.27%
FY20Y/Y Change
Revenue
7.4M
↑ 107.61%
Net Income
-59.8M
↑ 18.68%
Net Profit Margin
-805.88%
↑ 603.92%
FY21Y/Y Change
Revenue
4.7M
↓ 37.3%
Net Income
-70.5M
↑ 17.95%
Net Profit Margin
-1.5K%
↓ 710.16%
FY22Y/Y Change
Revenue
2.4M
↓ 49.32%
Net Income
-122.8M
↑ 74.13%
Net Profit Margin
-5.2K%
↓ 3693.25%
FY23Y/Y Change
Revenue
6.9M
↑ 192.02%
Net Income
-141.4M
↑ 15.19%
Net Profit Margin
-2.1K%
↑ 3154.53%
Q1 FY23Q/Q Change
Revenue
967.0K
↓ 40.05%
Net Income
-22.4M
↓ 5.39%
Net Profit Margin
-2.3K%
↓ 849.24%
Q2 FY23Q/Q Change
Revenue
268.0K
↓ 72.29%
Net Income
-30.5M
↑ 36.08%
Net Profit Margin
-11.4K%
↓ 9063.35%
Q3 FY23Q/Q Change
Revenue
1.5M
↑ 466.04%
Net Income
-38.3M
↑ 25.43%
Net Profit Margin
-2.5K%
↑ 8859.26%
Q4 FY23Q/Q Change
Revenue
4.1M
↑ 172.31%
Net Income
-43.3M
↑ 13.19%
Net Profit Margin
-1.0K%
↑ 1473.76%
Q1 FY24Q/Q Change
Revenue
156.0K
↓ 96.22%
Net Income
-32.8M
↓ 24.24%
Net Profit Margin
-21.0K%
↓ 19982.45%
Q2 FY24Q/Q Change
Revenue
2.5M
↑ 1501.28%
Net Income
-35.8M
↑ 9.25%
Net Profit Margin
-1.4K%
↑ 19595.94%
FY18Y/Y Change
Total Assets
155.8M
↓ 50.63%
Total Liabilities
31.7M
↓ 59.94%
FY19Y/Y Change
Total Assets
122.9M
↓ 21.1%
Total Liabilities
28.9M
↓ 8.95%
FY20Y/Y Change
Total Assets
235.8M
↑ 91.84%
Total Liabilities
26.5M
↓ 8.39%
FY21Y/Y Change
Total Assets
444.7M
↑ 88.54%
Total Liabilities
25.2M
↓ 4.92%
FY22Y/Y Change
Total Assets
352.7M
↓ 20.67%
Total Liabilities
26.5M
↑ 5.37%
FY23Y/Y Change
Total Assets
465.6M
↑ 32.0%
Total Liabilities
36.5M
↑ 37.41%
Q1 FY23Q/Q Change
Total Assets
324.5M
↓ 8.0%
Total Liabilities
21.8M
↓ 17.91%
Q2 FY23Q/Q Change
Total Assets
299.3M
↓ 7.77%
Total Liabilities
21.8M
↓ 0.02%
Q3 FY23Q/Q Change
Total Assets
280.3M
↓ 6.37%
Total Liabilities
33.5M
↑ 54.03%
Q4 FY23Q/Q Change
Total Assets
465.6M
↑ 66.14%
Total Liabilities
36.5M
↑ 8.7%
Q1 FY24Q/Q Change
Total Assets
868.8M
↑ 86.6%
Total Liabilities
30.2M
↓ 17.07%
Q2 FY24Q/Q Change
Total Assets
845.6M
↓ 2.68%
Total Liabilities
31.9M
↑ 5.6%
FY18Y/Y Change
Operating Cash Flow
-75.2M
↓ 24.71%
Investing Cash Flow
29.8M
↓ 35.84%
Financing Cash Flow
29.4M
↓ 42.6%
FY19Y/Y Change
Operating Cash Flow
-46.4M
↓ 38.31%
Investing Cash Flow
17.1M
↓ 42.72%
Financing Cash Flow
16.3M
↓ 44.78%
FY20Y/Y Change
Operating Cash Flow
-40.4M
↓ 12.95%
Investing Cash Flow
-98.2M
↓ 675.05%
Financing Cash Flow
171.2M
↑ 953.24%
FY21Y/Y Change
Operating Cash Flow
-60.9M
↑ 50.75%
Investing Cash Flow
-216.2M
↑ 120.08%
Financing Cash Flow
272.4M
↑ 59.07%
FY22Y/Y Change
Operating Cash Flow
-103.7M
↑ 70.31%
Investing Cash Flow
89.9M
↓ 141.61%
Financing Cash Flow
4.1M
↓ 98.5%
Q1 FY23Q/Q Change
Operating Cash Flow
-28.6M
↑ 31.28%
Investing Cash Flow
52.6M
↑ 68.42%
Financing Cash Flow
694.0K
↓ 50.25%
Q2 FY23Q/Q Change
Operating Cash Flow
-27.2M
↓ 4.81%
Investing Cash Flow
1.2M
↓ 97.79%
Financing Cash Flow
133.0K
↓ 80.84%

Technicals Summary

Sell

Neutral

Buy

Celldex Therapeutics, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
-29.67%
-27.28%
16.16%
-39.25%
1097.03%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
NA
NA
0.0
-2.44
-0.28
-0.18
NA
12.28
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Celldex Therapeutics, Inc.
Celldex Therapeutics, Inc.
Buy
$1.9B
1097.03%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Celldex Therapeutics, Inc.

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 156.0K → 2.49M (in $), with an average increase of 93.8% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -32.80M → -35.84M (in $), with an average decrease of 9.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 67.3%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 84.0%

Institutional Holdings

  • Wellington Management Company LLP

    12.18%

  • FMR Inc

    11.81%

  • BlackRock Inc

    7.08%

  • Vanguard Group Inc

    5.64%

  • Kynam Capital Management, LP

    5.11%

  • Eventide Asset Management, LLC

    5.02%

Corporate Announcements

  • Celldex Therapeutics, Inc. Earnings

    Celldex Therapeutics, Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Organization
Celldex Therapeutics, Inc.
Employees
160
CEO
Mr. Anthony S. Marucci M.B.A.
Industry
Health Technology

Discover More

FAQs